SWOG clinical trial number
S1900BDSS
S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS VCP)
Open
Abbreviated Title
S1900BDSS Version Control Protocol
Status Notes
The LUNGMAP S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS) is active effective 1/28/19.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
Activated
01/28/2019
Research committees
Lung Cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
95%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open